The NAGA Group AG
- WKN: A161NR
- ISIN: DE000A161NR7
- Land: Deutschland
Nachricht vom 24.11.2021 | 08:55
The NAGA Group AG plans NASDAQ IPO, publishes sales guidance for 2022 and announces changes to its regulated activities in the United Kingdom
The NAGA Group AG / Key word(s): IPO/Forecast
Ad hoc announcement according to Art. 17 Market Abuse Regulations
-The Naga Group AG plans NASDAQ IPO, publishes sales guidance for 2022 and announces changes to its regulated activities in the United Kingdom -
NAGA's IPO and listing in the US could be completed as early as the second half of 2022, subject to market conditions and other conditions. Details will be determined by NAGA at a later stage in the process. NAGA expects through the US IPO access to a much broader group of investors and to further significantly strengthen its profile on the capital market.
These efforts are supported by a continuously strong development of the operative business. For the financial year 2022, the company expects consolidated sales of EUR 95 million to EUR 105 million, which corresponds to a approx. doubling of the sales planned for 2021, as well as consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 25 million. up to EUR 30 million.
At the same time, the company announces that its direct business relationships in regards to regulated activities with UK-based customers of the companies within the group are to be terminated in the course of December. The UK's Financial Conduct Authority are aware of this change.
The resulting changes in sales and margins have already been taken into account in the above guidance.
|Company:||The NAGA Group AG|
|Hohe Bleichen 12|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1251570|
|End of Announcement||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
03. Dezember 18:19 Musterdepot-Titel BHP: Es geht voran
03. Dezember 19:02 Dow Jones: Es hört nicht auf...
03. Dezember 19:50 Commerzbank und Deutsche Bank: "Bitte keine großzügige ...
03. Dezember 20:20 Apple unter Druck – aber die Lage hellt sich langsam auf
03. Dezember 21:33 Schlussglocke: Dow Jones schließt schwache Woche mit weiterem Minus ab
News im Fokus
Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an
03. Dezember 2021, 07:03
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen
02. Dezember 2021